Antibacterial Use and Resistance in Psychiatric Hospitals

Antimicrobial stewardship in psychiatric hospitals presents a distinct infection-control problem. Patients may have reduced self-care capacity, prolonged exposure to inpatient environments, coexisting medical conditions, or medication-associated changes in immune function. Group activities and closed ward structures can also facilitate transmission. Against this background, the reference study examined how antibacterial drugs were used and how bacterial resistance appeared during the 2022 epidemic at a psychiatric hospital in Jiangsu, China.

The study is reported in Scientific Reports. Rather than evaluating one antibiotic or one pathogen, it combined drug-utilization indicators with microbiological and susceptibility data. That design makes the paper useful to researchers interested in hospital epidemiology, antimicrobial stewardship, and the interpretation of resistance data in specialized clinical settings.

Study Background and Research Question

The investigators began with a clinically important tension. COVID-19 increased concern about secondary bacterial infection, but broad-spectrum antibiotic exposure can select for resistant organisms when bacterial disease is unconfirmed or treatment is not sufficiently targeted. Psychiatric hospitals may be especially vulnerable because infection-control practices must operate alongside behavioral health care and long-term inpatient management.

The research question was therefore twofold: how extensively were antibacterial drugs used during the 2022 epidemic, and what resistance patterns were observed among bacterial isolates from the same hospital? The authors also sought to compare local utilization with Jiangsu Province and national monitoring data. This comparison helps distinguish hospital-specific prescribing patterns from wider regional or national trends.

Key Innovation from the Reference Study

The study’s central innovation is its integrated surveillance perspective. Antibiotic use was not assessed solely through expenditure or prescription counts. Instead, the authors considered antibiotic use rate, antibiotic use intensity, combined medication, cumulative defined daily doses, antibiotic expenditure, microbiological submission, pathogen identification, and drug susceptibility. These measures address different stages of stewardship: exposure, prescribing intensity, diagnostic support, and microbiological consequence.

This is particularly valuable in a psychiatric hospital, where low overall antibiotic consumption might otherwise be interpreted as evidence that resistance is unlikely to be a major concern. The paper demonstrates a more nuanced interpretation. The hospital used fewer antibiotics than the provincial and national benchmarks described by the authors, yet resistant phenotypes remained evident among both Gram-negative and Gram-positive organisms. Consequently, antibiotic volume alone is not a sufficient indicator of stewardship quality or future resistance risk.

The work also emphasizes diagnostic participation. A high microbiological submission rate provides a stronger basis for reassessing empirical therapy than prescription data alone. In practice, the study supports a feedback loop in which prescribing decisions, specimen collection, pathogen identification, and susceptibility testing are reviewed together.

Methods and Experimental Design Insights

The investigators used a retrospective observational design. Antibiotic-utilization data for 2022 were obtained from the hospital information system and the National Antibacterial Drug Clinical Application Monitoring Network. Hospital microbiology records supplied information on submitted specimens, positive pathogen identification, and drug-sensitivity testing. The analysis was conducted using Excel and organized around predefined utilization and resistance indicators.

The comparison framework included the study hospital, Jiangsu Province, and national data. This allowed the authors to position local performance against larger reference populations while retaining a detailed view of the hospital’s own antibiotic classes and resistance profile. The approach is relatively accessible for institutions that do not have advanced pharmacometric or machine-learning infrastructure, although its value depends on consistent data definitions and accurate microbiology reporting.

Protocol Parameters

• Study window: The analysis covered antibacterial use and microbiological records from calendar year 2022, as specified in the reference study.
• Data sources: Hospital information-system records were combined with national monitoring-network data and local pathogen susceptibility results.
• Utilization endpoints: The investigators evaluated antibiotic use rate, antibiotic use intensity, combined medication rate, cumulative DDDs, and the proportion of antibiotic costs within total drug costs.
• Diagnostic endpoint: The microbiological submission rate was used to estimate how often antibacterial treatment was supported by microbiological testing.
• Resistance endpoint: Resistance was summarized by pathogen group and antibiotic, with separate interpretation for Gram-negative and Gram-positive bacteria.
• Workflow interpretation: These are retrospective study parameters, not a prospective treatment protocol. For replication, laboratories should predefine denominators, specimen categories, duplicate-isolate rules, and susceptibility breakpoints before comparing hospitals or time periods.

A key methodological strength is the alignment of exposure and outcome data within the same institutional setting. A key methodological constraint is that retrospective data can identify patterns and associations but cannot by itself establish that a particular prescribing decision caused a subsequent resistance phenotype.

Core Findings and Why They Matter

Low overall utilization, but substantial surveillance activity

During 2022, the hospital reported an antibiotic use rate of 5.00%, antibiotic use intensity of 3.07, combined medication rate of 11.11%, cumulative antibiotic use of 12,039.04 DDDs, and antibiotic expenditure equal to 3.95% of total drug costs, according to the published analysis. The authors reported that these indicators were lower than corresponding levels in Jiangsu Province and nationwide.

However, the microbiological submission rate for antibacterial drug use was 77.78%, which the authors identified as higher than provincial and national comparisons. This distinction matters. A lower prescribing burden paired with more frequent microbiological testing may indicate a more evidence-oriented approach to treatment, but it does not eliminate the need to monitor resistance among the organisms that are recovered.

Dominant antibiotic classes

The principal antibiotic groups were third-generation cephalosporins, penicillins, and quinolones. By cumulative DDDs, cefodizime, amoxicillin, and piperacillin–tazobactam were among the most frequently used agents. These classes are clinically important because repeated exposure can exert selection pressure across a broad range of bacterial organisms, especially when treatment is empirical or prolonged.

The finding does not mean that use of these drugs was inappropriate in every case. Rather, it identifies the agents that should receive priority in prescription review, indication auditing, de-escalation analysis, and local antibiogram development. Utilization data can therefore guide stewardship resources toward the drugs most likely to influence local ecological pressure.

Resistance patterns differed by bacterial group

Gram-negative bacteria mainly showed resistance to penicillins, cephalosporins, and quinolones. The paper highlights ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin among the agents with notable resistance. Gram-positive bacteria mainly resisted penicillins, macrolides, and quinolones, with penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin emphasized in the reported pattern.

These results reinforce the importance of pathogen-specific interpretation. A single hospital-wide resistance percentage could conceal major differences between Gram-negative and Gram-positive organisms. The findings also show why quinolone and beta-lactam exposure should be evaluated alongside organism distribution, specimen source, ward location, and clinical indication rather than treated as isolated pharmacy metrics.

Interpretation for treatment and infection control

The authors describe a complex relationship between antibiotic use and resistance. Their conclusion is best understood as an association: increased antibiotic use in psychiatric settings may coincide with rising resistance and poorer treatment prospects, but the retrospective design cannot prove a direct causal pathway. Other contributors may include prior antibiotic exposure, colonization pressure, patient transfer, infection-control practices, specimen-selection bias, and changes in circulating organisms.

Even with those qualifications, the practical implication is clear. Regular analysis of resistance data should inform empirical treatment, while microbiological testing should be used to narrow or change therapy when results become available. This is especially important in institutions where delayed recognition of infection may increase the risk of complications or prolonged hospitalization.

Comparison with Existing Internal Articles

The internal article Antibacterial Use and Resistance in Psychiatric Hospitals During COVID-19 presents the same study as a data-driven stewardship problem, emphasizing comparisons among local, provincial, and national antibiotic-use levels. The present analysis extends that framing by focusing on the methodological relationship between utilization indicators and bacterial susceptibility results. Both perspectives agree that psychiatric hospitals require enhanced monitoring; neither supports interpreting low consumption as proof that resistance risk is negligible.

Because the internal article and the reference paper address the same evidence base, they should be treated as complementary summaries rather than independent replications. Researchers seeking new evidence should prioritize the original DOI-linked publication and examine whether later surveillance data show persistence or change in the reported patterns.

Limitations and Transferability

Several limitations affect how broadly the findings can be applied. First, the study represents one psychiatric hospital and one calendar year. Local prescribing policies, patient mix, ward structure, laboratory capacity, and referral patterns may differ substantially from those of general hospitals or other psychiatric institutions.

Second, the paper is retrospective. It identifies utilization and resistance patterns but does not randomize treatment, establish individual-level exposure histories, or demonstrate that a specific antibiotic caused resistance in a specific isolate. The data also do not fully resolve whether organisms represented infection, colonization, or contamination in every case.

Third, comparisons with provincial and national data depend on compatible definitions of antibiotic use, DDD calculation, microbiological submission, and susceptibility interpretation. Small changes in denominators or laboratory breakpoints can affect apparent differences. Future studies would benefit from longitudinal analyses, ward-level stratification, repeated-isolate handling, indication-specific prescribing review, and time-linked assessment of antibiotic exposure before culture collection.

Despite these constraints, the framework is transferable. A psychiatric hospital, rehabilitation facility, or other specialized institution can adapt the same sequence: quantify use, measure diagnostic support, characterize organisms, map resistance by drug class, and review the results with prescribers and infection-control teams. The most defensible transfer is methodological rather than numerical; the reported percentages should not be assumed to apply unchanged elsewhere.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

The reference paper concerns antibacterial stewardship and resistance, not lipid signaling or inflammatory pharmacology. Researchers may nevertheless pair infection models with separate host-response assays when studying how bacterial exposure affects inflammatory phenotypes. In that limited, cross-domain context, Gamma-linolenic acid, or GLA, may be relevant to anti-inflammatory research, apoptosis assay development, and disease-model workflows such as atopic dermatitis treatment or distal diabetic polyneuropathy research. These applications are adjacent to the reference study, not findings from it, and they should not be used to infer antibacterial activity or resistance reversal.

Researchers can use Gamma-linolenic acid (GLA), SKU C5518, to support similar cell-based inflammatory or lipid-signaling workflows that complement infection and microbiology experiments. Product information describes GLA as an omega-6 polyunsaturated fatty acid supplied in ethanol solution, with storage at −20°C and purity of at least 98%. Experimental users should validate solvent controls, dose range, exposure time, and assay compatibility in their own system; GLA is not a substitute for antimicrobial susceptibility testing or clinical antibiotic stewardship.